These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2670583)

  • 21. [In process].
    Hille-Rehfeld A
    Med Monatsschr Pharm; 2016 Oct; 39(10):444-5. PubMed ID: 29979543
    [No Abstract]   [Full Text] [Related]  

  • 22. Multidrug resistance and P-glycoprotein expression in human cancer.
    Ma DD; Bell DR
    Aust N Z J Med; 1989 Dec; 19(6):736-43. PubMed ID: 2576624
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of the cytotoxicity of some Mannich bases of acetophenone against the EMT6 tumour.
    Dimmock JR; Erciyas E; Raghavan SK; Kirkpatrick DL
    Pharmazie; 1990 Oct; 45(10):755-7. PubMed ID: 2089386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.
    Halfter K; Ditsch N; Kolberg HC; Fischer H; Hauzenberger T; von Koch FE; Bauerfeind I; von Minckwitz G; Funke I; Crispin A; Mayer B;
    BMC Cancer; 2015 Jul; 15():519. PubMed ID: 26169261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Golden medicinal plant].
    Praxis (Bern 1994); 2004 Sep; 93(38):1572. PubMed ID: 15495770
    [No Abstract]   [Full Text] [Related]  

  • 26. Prediction of response to drug therapy of cancer. A review of in vitro assays.
    Bellamy WT
    Drugs; 1992 Nov; 44(5):690-708. PubMed ID: 1280562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vivo and in vitro effects of GnRH analogs on ovarian Leydig cell tumor].
    Emons G; Ortmann O; Pahwa GS; Löhrs U; Wetterling T; Dilling H; Oberheuser F; Knuppen R
    Geburtshilfe Frauenheilkd; 1992 Aug; 52(8):487-93. PubMed ID: 1327941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of resistance and cross-resistance to cytotoxic agents by tumour cell lines.
    Mattern J; Edler L; Volm M
    Anticancer Res; 1989; 9(4):833-6. PubMed ID: 2817810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Resistance of cancer cells to antineoplastic agents. Can the efficiency of chemotherapy be predicted?].
    Bénard J
    Rev Prat; 1992 Feb; 42(3):318-9. PubMed ID: 1579821
    [No Abstract]   [Full Text] [Related]  

  • 30. The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs--an in vitro study using EMT6 multicellular spheroids.
    Kwok TT; Twentyman PR
    Int J Cancer; 1985 May; 35(5):675-82. PubMed ID: 3997287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
    Walker J; Martin C; Callaghan R
    Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anticancer immunoconjugates: current status and prospects].
    Zhen YS
    Yao Xue Xue Bao; 1994; 29(1):1-8. PubMed ID: 8036894
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of Tumor Penetration of Podophyllotoxin-Carboxymethylcellulose Conjugates with Various Chemical Compositions in Tumor Spheroid Culture and In Vivo Solid Tumor.
    Yang Y; Roy A; Zhao Y; Undzys E; Li SD
    Bioconjug Chem; 2017 May; 28(5):1505-1518. PubMed ID: 28437080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.
    Eisenberger MA; Fontana JA
    J Natl Cancer Inst; 1992 Jan; 84(1):3-5. PubMed ID: 1738171
    [No Abstract]   [Full Text] [Related]  

  • 35. Lonidamine: in vitro/in vivo correlations.
    Teicher BA
    Eur J Cancer; 1994; 30A(10):1411-3. PubMed ID: 7833093
    [No Abstract]   [Full Text] [Related]  

  • 36. Endocrine pharmacology of antiestrogens as antitumor agents.
    Jordan VC; Murphy CS
    Endocr Rev; 1990 Nov; 11(4):578-610. PubMed ID: 2292243
    [No Abstract]   [Full Text] [Related]  

  • 37. Cytotoxic drug resistance: molecular basis and clinical significance.
    Twentyman PR; Bleehen NM
    BJR Suppl; 1992; 24():84-8. PubMed ID: 1363273
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapy and disease concepts: the history (and future?) of antimony in cancer.
    Duffin J; Campling BG
    J Hist Med Allied Sci; 2002 Jan; 57(1):61-78. PubMed ID: 11892514
    [No Abstract]   [Full Text] [Related]  

  • 39. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro.
    Colston KW; Mackay AG; James SY; Binderup L; Chander S; Coombes RC
    Biochem Pharmacol; 1992 Dec; 44(12):2273-80. PubMed ID: 1472092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo.
    Szade K; Zukowska M; Szade A; Collet G; Kloska D; Kieda C; Jozkowicz A; Dulak J
    Tumour Biol; 2016 Feb; 37(2):2481-96. PubMed ID: 26385771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.